交付通过喷射注射编码SARS-CoV-2的RBD的实验mRNA疫苗
D N Kisakov1, L A Kisakova2, S V Sharabrin2
1State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia. def_2003@mail.ru.
Bulletin of experimental biology and medicine
|June 19, 2024
概括
针对SARS-CoV-2的实验mRNA疫苗 (mRNA-RBD) 的无针喷射引发了小鼠的强有力的免疫反应,超过了传统的肌肉内输送. 这种方法为mRNA疫苗输送提供了安全有效的替代方案.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 脂质纳米颗粒 (LNP) 通常用于mRNA疫苗的输送.
- 肌肉内注射是许多疫苗的标准输送途径.
- SARS-CoV-2 mRNA 疫苗已经显示出显著的疗效.
研究的目的:
- 评估无针喷射注射作为编码SARS-CoV-2受体结合域 (mRNA-RBD) 的实验mRNA疫苗的输送方法.
- 为了比较通过喷射注射和肌肉内注射输送的mRNA-RBD的免疫性.
主要方法:
- 在BALB/c小鼠中,使用无针喷射器用mRNA-RBD进行免疫接种.
- 对照组接受了肌肉内注射mRNA-RBD.
- 评估了幽默 (抗体) 和细胞 (T细胞) 免疫反应.
主要成果:
- 对mRNA-RBD的喷射注射引起了高水平的病毒中和抗体.
- 在喷射注射后观察到显著的病毒特异性T细胞反应.
- 肌肉内输送mRNA-RBD导致免疫反应较低.
结论:
- 无针喷射注射是提供mRNA疫苗的有效和安全方法.
- 喷射mRNA疫苗可以成为基于LNP的输送系统的可行替代方案.
- 这种交付方法需要进一步研究潜在的临床应用.
更多相关视频
08:27Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
Published on: August 13, 2021
4.5K
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
相关概念视频
02:15Experimental RNAi
6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
01:23Vaccine Production
144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144